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ABSTRAK
Cisplatin adalah agen kemoterapi untuk pasien kanker serviks yang menerima radiasi sebagai terapi utama. Salah satu efek samping
cisplatin adalah gangguan elektrolit, yang menurunkan tingkat magnesium dan kalium. Namun, efektivitas penerapan suplementasi
parenteral MgSO4 dan KCl sebagai hipomagnesemia dan hipokalemia profilaksis masih dipertanyakan. Penelitian ini bertujuan
mengevaluasi efektivitas suplementasi magnesium dan kalium serum pada pasien kanker serviks yang menerima cisplatin 50 mg/m2.
Penelitian ini merupakan penelitian observasional dengan metode cross-sectional. Kriteria inklusi adalah pasien kanker serviks
stadium IIB yang akan menerima siklus keempat. Semua pasien (n = 22 pasien) menerima 1.000 cc saline normal (NS) hidrasi, tetapi
hanya pasien pada kelompok perlakuan (n = 11 pasien) menerima suplemen MgSO4 (0,5 g) dan KCl (10 mEq) bersama dengan
hidrasi pasca-kemoterapi. Data yang diperoleh adalah kadar magnesium, kalium, kreatinin, dan serum BUN, masing-masing diukur
sebelum dan sesudah kemoterapi cisplatin siklus keempat. Hasilnya, pada kelompok kontrol sebelum siklus keempat, tingkat
magnesium serum adalah 1.87 ± 0.22 mg/dL sedangkan kalium 4.15 ± 0.71 mmol/L. Pasca siklus keempat, kadar magnesium serum
1,75 ± 0,19 mg/dL sedangkan kalium 4,21 ± 0,67 mmol/L. Pada kelompok perlakuan sebelum siklus keempat, kadar magnesium
serum 1,95 ± 0,25 mg/dL sedangkan kalium 4,06 ± 0,36 mmol/L. Pasca siklus keempat, kadar magnesium serum 1,85 ± 0,16 mg/dL
sedangkan kalium 4,01 ± 0,28 mmol/L. Simpulan, kedua kelompok menunjukkan tidak ada perbedaan signifikan pada kadar serum
magnesium dan kalium. Tidak ada manifestasi klinis hipomagnesemia atau hipokalemia terjadi pada tiap pasien. (FMI
2014;50:172-178)
Kata kunci: cisplatin, gangguan elektrolit, serum magnesium, serium kalium, suplementasi
ABSTRACT
Cisplatin is a chemotherapeutic agent for cervical cancer patients receiving radiation as the main therapy. One of cisplatin’s side
effects is electrolyte disturbance, which is decreasing magnesium and potassium level. However, the application of MgSO4 and KCl
parenteral supplementation effectiveness as the hypomagnesaemia and hypokalemia prophylaxis remained in question. This study
was to evaluate magnesium and potassium parenteral supplementation effectiveness on magnesium and potassium serum level in
cervical cancer patients receiving cisplatin 50 mg/m2. This was an observational study using cross-sectional method. The inclusion
criteria was IIB stage cervical cancer patients who were going to receive the fourth cycle. All patients (n=22 patients) received 1000
cc normal saline (NS) hydration, but only patients in treatment group (n=11 patients) received MgSO4 (0.5 g) and KCl (10 mEq)
supplementation together with post-chemotherapy hydration. Data obtained were magnesium, potassium, creatinine, and BUN serum
concentration, each was measured pre- and post-fourth cycle cisplatin chemotherapy. Results, in pre-fourth cycle control group,
magnesium serum level was 1.87 ± 0.22 mg/dL while potassium was 4.15 ± 0.71 mmol/L. In post-fourth cycle, magnesium serum was
1.75 ± 0.19 mg/dL while potassium was 4.21 ± 0.67 mmol/L. In pre-fourth cycle treatment group, magnesium serum was 1.95 ± 0.25
mg/dL while potassium was 4.06 ± 0.36 mmol/L. In post-fourth cycle, magnesium serum was 1.85 ± 0.16 mg/dL while potassium was
4.01 ± 0.28 mmol/L. In conclusions, both groups showed no significant difference in magnesium serum and in potassium levels. No
clinical manifestation hypomagnesaemia or hypokalemia appeared in any patient. (FMI 2014;50:172-178)
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INTRODUCTION
Cancer of the cervix can be defined as the malignant
transformation of the cervix uteri. The most common
cause is human papilloma virus (HPV) infection
(Cherath et al 2005, DeCherney et al 2007). Treatment
for cervical cancer can be either surgery, radiation, or
chemotherapy according to the stage and tissue
metastases (Cherath et al 2005). National Cancer
Institute recommend cisplatin-based as the
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chemotherapy given concurrently with radiation therapy
for cervical cancer (Monk & Tewari 2007). Cisplatin
nephrotoxicity is dose-related, cumulative, and usually
reversible. Acute nephrotoxicity caused by cisplatin is
characterized by decreased mitochondrial function,
decreased ATPase activity; altered cell cation content,
altered solute transport; persistent losses of sodium,
magnesium (Mg), potassium (K), calcium, water;
decreased renal blood flow (RBF) and glomerular
filtration rate (GFR); increased serum creatinine (SCr);
and increased blood urea nitrogen (BUN). These events
precede renal architectural alterations (Stewart et al
1985, Cornelison & Reed 1993, Tiseo et al 2007,
Arunkumar et al 2011). The major site of cisplatin-
induced damage in the kidney is generally felt to be the
part of proximal and distal tubule, but collecting duct
sometimes can also be affected. This impairment of the
tubule is believed to cause the occurrence of body
electrolyte imbalance (Stewart et al 1985, Zekri et al
2009). According to a study, the most common
manifestation of nephropathy is mild hypomagnesaemia
grade 1 which occurs significantly after fourth or fifth
cycle of chemotherapy (Anvari et al 2010, Mashhadi et
al 2013). Hypomagnesaemia occurs because of elevated
magnesium excretion as the result of decrease Mg
reabsorption in the proximal tubule and collecting duct
(Cornelison & Reed 1993). It is known that cisplatin
treatment can cause up to 90% Mg deficiency in patient
who does not acquire Mg supplement as prophylaxis
(Gaby 2009). In the beginning, Obstetric and
Gynecologic ward Dr. Soetomo Hospital applies only
75 mg/m2 cisplatin-based chemotherapy together with
2000 cc normal saline (NS) hydration.
Then 50 mg/m2 dose is also used as a combined therapy
while the patient is waiting for radiotherapy, because
radio-therapy device is limited. This fact makes a large
amount of cisplatin dose 50 mg/m2 chemotherapy
usage. The protocol used is based on BC Cancer
Agency (BCCA) that is dose 40-60 mg/m2 needs 1000
cc NS hydration for more than 1 hour with parenteral
supplementation of MgSO4 0.5 g and KCl 10 mEq (BC
Cancer Agency Drug Manual 2008). This was an
observational, cross-sectional study for evaluating the
effect of parenteral supplementation of MgSO4 0.5 g
and KCl 10 mEq towards magnesium and potassium
serum level in cervical cancer patients receiving
cisplatin single dose 50 mg/m2 as neo-adjuvant
chemotherapy which had never been held before.
MATERIALS AND METHODS
This observational cross-sectional study is conducted
for 4 months (June - September 2013). Population
subject were cervical cancer patients who were
hospitalized in Obstetric & Gynecologic ward in Dr.
Soetomo Hospital. Patients were elected by consecutive
sampling, we took every patient who fulfills the criteria.
Later they were divided into 2 groups, which are control
(patients did not acquire MgSO4 0.5 mg and KCl 10
mEq supplementation after obtained each cycle of
chemotherapy) and treatment (patients acquired MgSO4
0.5 mg and KCl 10 mEq supplementation after obtained
each cycle of chemotherapy). Patients got chemotherapy
once a week. Prior to the fourth cycle, patients’ Mg and
K serum level were evaluated as a pre data and one
week afterward they were evaluated again as a post
data. Each group consists of 11 patients.
Inclusion criteria for this study were IIB stage cervical
cancer patients treated with single dose cisplatin 50
mg/m2 who were ready for the fourth cycle and always
got the same chemotherapy regimen since the first
cycle; women more than 21 years old who were willing
to sign informed consent. While exclusion criteria
included patients whose respiration rate less than 16
times/min; hypotensive patients (blood pressure < 90/60
mmHg); patients with decreased or without patella
reflex; and patients suffer from diabetes mellitus.
Data Analysis  and Statistics
For analyzing the alteration of Mg and K serum level
between pre and post data, we used paired t-test for
normal distribution and Wilcoxon test for the other one.
While to compare effect supplementations on Mg and K
serum level between two groups, we used independent
t-test if the distribution is normal and Mann-Whitney
test if it is not normal. We used the differences between
pre and post data as parameters.
RESULTS
Number of samples who fulfill inclusion criteria from
June until September 2013 were 22 patients, divided
into 11 patients for control group and 11 patients for
treatment group. Sample of study characteristics are
shown in Table 1.
Pre-data was collected before patients endured fourth
cycle chemotherapy, because a study concluded that the
most significant decline of Mg and K serum level
because of cisplatin-based chemotherapy occurred after
the third cycle, while post-data was collected a week
after patients endured the fourth cycle. Data of Mg and
K serum level are shown in Table 2.
Statistical analysis used to compare Mg and K serum
level between pre-data and post-data is paired t-test. The
results of this test are shown in Table 3. There was no
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significant change between pre- and post-data in control
group either for Mg serum level (p = 0.065) or K serum
level (p = 0.705). In treatment group there was also no
significant change between pre- and post-data either for
Mg serum level (p = 0.104) or K serum level (p =
0.574).
Table 1. Sample of study characteristics
Patients’ Characteristics Number of
Patients
(N = 22)
%
Age (years)
Average = 48.7 (36-64)
Range 30-40
Range 41-50
Range 51-60
Range 61-70
2
14
4
2
9.09
63.64
18.18
9.09
Range of GFR Level
≥ 60 cc/min
50-59.99 cc/min
< 50 cc/min
16
6
–
72.73
27.27
–
Range of Body Mass Index
18.5-22.9 kg/cm2
23-24.9 kg/cm2
≥ 25 kg/cm2
10
3
9
45.45
13.64
40.91
Meanwhile, we calculated the difference of pre- and
post-data for both Mg and K serum level to compare the
change between control and treatment group. Statistical
analysis used to compare these groups is independent t-
test. Table 4 showed the result of statistical test to
evaluate the effect of MgSO4 (0.5 g) and KCl (10 mEq)
parenteral supplementation between control and
treatment group which did not statistically give any
significant difference, for either Mg serum level (p =
0.914) or K serum level (p = 0.539).
DISCUSSION
Cisplatin is an antineoplastic drug used in the treatment
of many solid-organ cancers, including those of the
head, neck, lung, testis, ovary, and breast (Miller et al
2010). According to the protocol used in Obstetric-
Gynecologic Department in Dr. Soetomo Hospital,
single dose cisplatin 50 mg/m2 regimentation is applied
as neo-adjuvant therapy (NAC) for cervical cancer stage
IB2 or more, which is given weekly. This study was
conducted since June until September 2013, involving
woman patients with cervical cancer stage IIB who
acquired single dose cisplatin 50 mg/m2 chemotherapy
as NAC. Inclusion criteria were patients had received 3
chemotherapy cycles and were going to endure the
fourth cycle. This was an observational with cross-
sectional assessment study.
Table 2. Magnesium and Potassium Serum Level
Average Control Group
(n = 11)
Average Treatment Group
(n = 11)Observation
Pre 4th Cycle Post 4th Cycle Pre 4th Cycle Post 4th Cycle
Mg (mg/dL) 1.87 ± 0.22 1.75 ± 0.19 1.95 ± 0.25 1.85 ± 0.16
K (mmol/L) 4.15 ± 0.71 4.21 ± 0.67 4.06 ± 0.36 4.01 ± 0.28
SCr (mg/dL) 0.95 ± 0.08 1.00 ± 0.17 0.88 ± 0.17 0.92 ± 0.17
BUN (mg/dL) 11.00 ± 3.77 12.45 ± 4.76 14.00 ± 7.17 12.09 ± 3.59
Table 3. Statistical Analysis between Pre- and Post- Fourth Cycle Chemotherapy
Control Group Treatment GroupParameter Average ± Sd T-Count Significant Value Average ± Sd T-Count Significant Value
Mg Level 0.118 ± 0.189 2.076 0.065 0.109 ± 0.202 1.789 0.104
K Level -0.064 ± 0.541 -0.390 0.705 0.055 ± 0.311 0.582 0.574
Table 4. Statistical Analysis of the Difference of Magnesium and Potassium Serum Level between Control and
Treatment Groups
Magnesium Serum Level Kalium Serum LevelGroup Average ± Sd T-Count Significant Value Average ± Sd T-Count Significant Value
Control -0,118 ± 0,189 0,064 ± 0,541
Treatment -0,109 ± 0,202 -0,109 0,914 -0,055 ± 0,311 0,628 0,539
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We chose patients with cervical cancer stage IIB as an
inclusion criterion because they would receive cisplatin
chemotherapy weekly. The range of patients’ ages
which involved in this study was between 36-64 years
old (average = 48.7 years old), with the most common
incidence occurred in range 41-50 years old. In this
case, age was not one of the risk factors affecting the
development of cervical cancer disease (Parra et al
2006, Beckmann et al 2010, Dizon & Campos 2011).
Besides, age also did not affect any Mg metabolism in
plasma (Lajer et al 2003). But, according to the data
acquired by Asia Oceania Research Organization in
Genital Infection and Neoplasia (OAGIN), it is known
that commonly this disease occurs in 40-50 years old
women, with incubation period estimated approximately
7-10 years. It means that the patients began to be
infected by human papilloma virus (HPV) in productive
age about 30-40 years old.
This study focused on the evaluation of the
effectiveness application of MgSO4 (0.5 g) and KCl (10
mEq) for patients who acquiring cisplatin chemo-
therapy, with Mg and K serum level as measuring
parameters. Evaluation was conducted when patients
were going to endure the fourth cycle chemotherapy
(pre-data) and after patients got the fourth cycle
chemotherapy (post-data).
Based on the routine procedure, every patient acquiring
50 mg/m2 dose cisplatin with GFR ≥ 60 cc/minute
would also receive NS hydration 500 cc each pre- and
post-chemotherapy. Together with hydration after
chemotherapy, patients also received 0.5 g MgSO4 and
10 mEq KCl supplementation. This protocol refers to
the BC Cancer Agency (BCCA). The hydration was
given to prevent cisplatin ligand exchange and advance
damage caused by platinum-protein bond. Besides, NS
‘hydration also applied in purpose to shorten the contact
time between drug and renal tubule. NS hydration
becomes the most important strategy to protect and
maintain renal function (Cornelison & Reed 1993).
Cisplatin chemotherapy toxicities include ototoxicity,
gastrotoxicity, allergic reaction, myelosuppression, and
the main dose-limiting side effect, nephrotoxicity
(Miller et al 2010). Acute renal failure can be occurred
even in low-dose cisplatin which is given routinely.
This condition is caused by free cisplatin which does
not bond with plasma protein will be infiltrated freely in
glomerulus (because of the low molecular weight),
accumulated, and finally injured renal function
(Launay-Vacher et al 2008, Moon et al 2011). Besides,
necrosis on major nefron can also disturb electrolyte
balance (Arunkumar et al 2011). Cisplatin is known as
cytotoxic agent which often cause electrolyte imbalance
(Zekri et al 2009). Direct injury at loop of Henle, either
in ascending or descending is believed as the
mechanism causing hypomagnesaemia. While hypo-
kalemia can be occurred because of increase renal
reabsorption capacity as a respond of decrease
potassium absorption in intestinal (Arunkumar et al
2011).
Magnesium serum level in both control and treatment
group decreased after patients got the fourth cycle
chemotherapy. But statistically no difference shown by
paired t-test analysis between pre-data and post-data.
Although both of them endured the same decrease, Mg
serum level in treatment group was higher than in
control group. However, according to the independent t-
test analysis, there was no significant difference
between Mg serum level in control and in treatment
group. Uncontrollable patients’ intake while they were
at home became one of the factors affecting this
condition, besides the degree of nausea/vomiting which
happened in patients. Degree of nausea/vomiting could
affect Mg serum level because excessive vomiting will
cause Mg deficiency (Zekri et al 2009). According to
the patients’ assessments, it was known that
nausea/vomiting happened more frequently in treatment
group (9 patients) than in control group (5 patients). A
literature stated that body Mg surplus can cause
vomiting and constipation (Lang 2000).
In the other hand, severe nausea/vomiting occurred in
most patients may also because of cisplatin is high
emetogenic drug. That severe nausea/vomiting (> 90%)
could occur immediately or delayed. Risk of
nausea/vomiting because of cisplatin increase in woman
patients, young patients, high-dose cisplatin application,
and rapid infusion. Nausea/vomiting could also affect
patients’ intake by decreasing their appetite. Most of
patients complained for 3-5 days decrease of appetite
after chemotherapy.
A study concluded that plasma Mg cannot be the only
reliable parameter used to measure total body Mg
reserved, Mg depletion, and supplementation treatment,
because most Mg is stored in intracellular element and
only about 0.3% of total body Mg appears in plasma
(Lajer et al 2003, Anvari et al 2010). In his study,
Macaulay et al (1982) also met progressively decrease
of Mg serum level even in group of patients who
received supplementation either orally or intravenously.
Meanwhile, hypokalemia is a common condition
occurred in cisplatin-based chemotherapy because of
incline renal reabsorption capacity as a result of
decrease K absorption in intestine (Arunkumar et al.,
2011). Based on statistical analysis used in this study,
there was no significant difference in K serum level
between post- and pre-fourth cycle chemotherapy.
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Increased K excretion was caused by increasing K
secretion (via sodium-load dependent potassium
mechanism) by means to increase sodium, potassium,
and water concentration in distal segment of renal,
because of the decrease sodium reabsorption in
proximal tubule. Furthermore, loss of renal potassium
and calcium is the secondary result of Mg deficiency
(Cornelison & Reed 1993).
There is a related link between hypomagnesaemia and
hypokalemia: the decrease of intracellular Mg which is
caused by Mg deficiency will mediate renal outer
medullary potassium (ROMK) channel inhibition by Mg
and increase K secretion. Besides, Mg deficiency will
disturb Na-K-ATPase regulation and decrease uptake
K+ into cells. Decrease of cellular K+ uptake if occurs
concomitantly with increase either gastrointestinal
excretion or urinary will cause K+ loss and hypo-
kalemia. About 50% hypokalemia incidence occurs
together with Mg deficiency. Mg and K are the most
abundant cations in intracellular which function to
stabilize potential membrane and decrease cell
excitation. Mg plays an important role in K intracellular
balance. Hypokalemia affecting tissue will be more
severe and refractory if preceded by Mg deficiency
(Huang & Kuo 2007, Zekri et al 2009).
Evaluation of the effectiveness MgSO4 and KCl
supplementation in patients receiving cisplatin
chemotherapy was conducted by comparing between 2
groups of patients. In control group, patients receiving
cisplatin did not acquire MgSO4 (0.5 g) and KCl (10
mEq) supplementation at all during enduring all four
cycles of chemotherapy, while treatment group
consisted of patients who received MgSO4 (0.5 g) and
KCl (10 mEq) supplementation in each cycle of
chemotherapy during enduring 4 cycles of cisplatin
chemotherapy. After conducting statistical analyzes
using independent t-test, we gained a conclusion that
MgSO4 and KCl supplementation gave a significant
difference neither in Mg nor in K serum level in patients
who received that supplementation when compared with
patients who did not.
A study stated that although Mg supplementation
appears to be beneficial for all patients, it is likely that
the greatest benefit will be to patients with large volume
metastatic disease who may require prolonged treatment
with cisplatin (Willox et al 1986). Study conducted by
Lajer et al. in 26 patients with cisplatin treatment results
a significant difference in Mg plasma measurement
between before and after chemotherapy, and also for
intracellular K in skeletal muscle biopsy. But there was
no significant difference in K plasma between before
and after chemotherapy. This study also showed that
there was a correlation between Mg and K plasma
which each was measured after chemotherapy (Lajer et
al 2003). In other hand, a study conducted by Macaulay
et al (1982) concluded that supplementation applied
intravenously in a short time could not compensate
variable patients’ food intake for a long time. On the
contrary, that supplementation will lead to increasing
urinary Mg loss while maintaining Mg serum level in
the normal range. It seems that urinary Mg loss
happened in patients was resulted from the large amount
of liquid given besides from renal injury because of
cisplatin (Macaulay et al 1982).
Although there was no statistically significant result in
this study, the results showed that there was an
increasing K serum level after fourth cycle
chemotherapy in control group. This condition may be
caused of decreasing renal function which was showed
from much lower GFR value (calculated with Cockroft-
Gault formula) in control group than in treatment group.
Decreasing renal function until renal impairment
becomes the most common cause of hyperkalemia,
because K excretion by renal is an important defense
mechanism towards chronic K disturbance (Freshwater-
Turner et al 2008). This depends on the glomerular free
filtration, huge amount of reabsorption in proximal
tubule, also secretory regulation process in distal
convoluted tubule, cortical collecting duct, and outer
medullary collecting duct.
Cortical collecting duct and outer medullary collecting
duct consist of at least 2 types of different cells, termed
principal cells and intercalated cells. Principal cells,
which comprise approximately 70-75% of collecting
duct cells, mediate sodium reabsorption and potassium
secretion and are targets for angiotensin II, aldosterone,
aldosterone receptor antagonists, and potassium-sparing
diuretics. Principal cells exploit the electrochemical
gradient established by sodium entry into the cell
through a sodium channel at the luminal membrane and
the basolateral membrane Na-K-ATPase to drive
potassium secretion through 2 classes of luminal
membrane potassium channels. The other collecting
duct cell type, intercalated cells, mediate acid-base
transport but upregulate expression of luminal H,K-
ATPases during potassium depletion to enhance
potassium reabsorption (Greenlee et al 2009). Renal
impairment will disturb K homeostasis regulation
(Freshwater-Turner et al 2008).
Meanwhile, there was decreasing in K serum level in
treatment group. Nausea/vomiting incidents occurred
longer and more common in patient in the treatment
group. Vomiting can cause decrease body K level. This
is not because of loss K from vomiting, but because of
loss H+ and water which leads to metabolic alkalosis
and aldosterone increasing. When extracellular body pH
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increases, the cells release H+ in exchange for Na+
(Na+/H+ exchangers) and pump the Na+ out again in
exchange for K+ (Na-K-ATPase). This K+ uptake by
the cells causes hypokalemia (Lang 2000). Meanwhile,
aldosterone plays a role to increase Na-K-ATPase
activity in distal tubule and collecting duct (Freshwater-
Turner et al 2008).
There was also a chance that intracellular K was not in
balance state during cisplatin treatment. When
hypokalemia occurs, body activates some mechanisms
to maintain body K level, especially by renal role.
Besides, skeletal muscle and liver can also be a buffer
toward alteration of plasma K concentration by means
of transcelullar K redistribution and feedback control
for renal K excretion. Na-K-ATPase actively pumps K
into cells and maintains extracellular electrochemical
gradient in normal range between 3.5-5.0 mmol/L and
intracellular K concentration around 150 mmol/L,
which is very important for excitable cells function. -
catecholamines, aldosterone, insulin, pH, and osmolality
can also affect transcelullar K distribution. By that
function, they help to restabilize alteration of K
concentration which ever occurred in plasma (Greenlee
et al 2009).
Measurement of hyperkalemia severity can be
determined by its symptoms, plasma K concentration
(although this value is not representative enough), and
electrocardio-graphy abnormality. But to determine
more precisely the cause of K loss from renal, trans-
tubular potassium concentration gradient (TTKG) can
be conducted. TTKG is calculated by comparing K+
concentration in lumen of cortical collecting duct with
K+ concentration in peri-tubular capillary or plasma.
The validity of measurement is affected by the number
of solute reabsorbed in medullary collecting duct,
neither secreted nor reabsorped K+ in medullary
collecting duct, and the amount of liquid osmolality in
the edge of cortical collecting duct. Hypokalemia state
with TTKG value > 4 indicates that loss of renal K+ is a
result from increasing distal K+ secretion.
Hypomagnesaemia may become symptomatic, with
muscle irritability or cramps, clonus, tremor, carpo-
pedal spasm and/or tetany (BC Cancer Agency Drug
Manual 2008, Jahnen-Dechent & Ketteler 2012), while,
excessive Mg concentration in body can lead to Mg
intoxication with such symptoms as constipation,
vomiting, hypotension, neuromuscular dysfunction,
hypotonia, atonia, even respiratory depression (Lang
2000, Jahnen-Dechent & Ketteler 2012). These
symptoms often occur in ecclampsia treatment with
MgSO4 as seizure prophylaxis.
In this study, we also observed patients’ clinical
condition after chemotherapy was given together with
its hydration and supplementation, but there was none
of them showed these symptoms. A literature stated that
even in a patient with severe hypomagnesaemia, clinical
symptoms related to Mg deficiency do not likely appear
(Jahnen-Dechent & Ketteler 2012).
Besides K, Mg existence in the body can also affect
body calcium regulation. Then to precisely determine
electrolyte imbalance, calcium serum level may become
an alternative measurement, considering that Mg
existence in extracellular fluid is not quite amount
enough. Uncontrollable patients’ food intake while they
were at home became a limitation for this study,
because it might affect Mg and K serum level when the
patients returned to the hospital a week later.
CONCLUSION
Magnesium and potassium parenteral supplementation
does not produce significant effect on magnesium and
potassium serum level of cervical cancer patients
receiving cisplatin chemotherapy.
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